Announcements Trials
Browse Landscape

Phase

Phase 1 4

Status

Completed 2Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other solid neoplasm 4

Conditions

Carcinoma, Non-Small-Cell Lung 4Advanced Solid Tumors 4Squamous Cell Carcinoma of Head and Neck 3Carcinoma, Renal Cell 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Stomach Neoplasms 2Ovarian Neoplasms 2Melanoma 2Esophageal Neoplasms 2Triple Negative Breast Neoplasms 1Solid Tumors 1Solid Tumor, Unspecified, Adult 1Solid Tumor 1Pharyngeal Neoplasms 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms 1Multiple Myeloma 1Mouth Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Laryngeal Neoplasms 1Kidney Neoplasms 1Hypopharyngeal Neoplasms 1Head and Neck Neoplasms 1Erythrocytosis, Familial, 4 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Merkel Cell 1

Interventions

Injections 18Carboplatin 14Docetaxel 11pembrolizumab 8durvalumab 7Cisplatin 6linifanib 5Paclitaxel 5Nivolumab 5zimberelimab 4talazoparib 4olaparib 4Panobinostat 4Itraconazole 4Bevacizumab 4tremelimumab 3sintilimab 3depatuxizumab 3atezolizumab 3ST 1481 3S 1 (combination) 3Rifampin 3Pemetrexed 3Oxaliplatin 3Fluorouracil 3Everolimus 3Drug Therapy 3trifluridine tipiracil drug combination 2trametinib 2toripalimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Advanced Solid Tumors × zimberelimab × Clear all
NCT06532565 2026-04-21

Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors

Gilead Sciences

Phase 1 Recruiting
154 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT04087018 2024-09-19

Study to Evaluate Safety and Clinical Activity of AB122 in Biomarker Selected Participants With Advanced Solid Tumors

Arcus Biosciences, Inc.

Phase 1 Completed
18 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT04747470 2024-09-03

Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors

Gilead Sciences

Phase 1 Terminated
13 enrolled 18 charts
Other solid neoplasm

Advanced Solid Tumors

NCT03713905 2023-04-10

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors

Guangzhou Gloria Biosciences Co., Ltd.

Phase 1 Completed
293 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡